Antibodies are an important class of glycoproteins. Compelling experimental data have shown that the fine structures of the highly conserved Fc glycans in IgG type antibodies can have profound effects on the antibody?s biological functions and, in the case of therapeutic antibodies, the clinical efficacy, such as antibody-dependent cellular cytotoxicity (ADCC), complement- dependent cytotoxicity (CDC), activation of apoptosis, and anti-inflammatory activities. More recently, it was reported that a single oligomannose type glycan at the IgE-Fc domain was responsible for high-affinity binding to IgE receptor on mast cells and was critical for initiation of allergic reactions. However, progress in understanding the functional roles of antibody glycosylation is hampered by the tremendous structural heterogeneity of Fc glycosylation. Gnetic approach to glycoengineering has achieved some successes but the antibody glycoforms that can be generated by genetic approach are limited. Currently there is no general method avaiable to control glycosylation to a pre-defined homogeneous form during recombinant antibody production. In this application, we propose to explore a chemoenzymatic method that we recently developed to make various homogeneous IgG and IgE glycoforms. Through performing Fc receptor binding studies, we aim to understand how different glycan structures modulate the effector functions of IgG and IgE and to apply the knowledge obtained for developng better therapeutics.
Three specific aims are proposed to achieve the goal.
Aim 1 is to further explore the chemoenzymatic method for antibody glycoengineering by investigating enzyme structures, searching for new enzymes and mutants, and evaluating new glycan substrates.
Aim 2 is to establish a general site-specific conjugation method for constructing homogeneous antibody-drug conjugates. Functional tags will be introduced to Fc glycan site- specifically and a toxin will be chemoselectively ligated to the Fc glycan to provide homogeneous ADCs.
Aim 3 is to perform site-specific glycosylation remodeling of IgE Fc for probing the glycosylation functions in allergic reactions. A successful pursuit of the proposed research could lead to the creation of new IgG and IgE glycoforms with novel biological properties. The chemoenzymatic method may become a general platform technology for site- specific antibody-drug conjugation and labeling. The study on IgE Fc glycosylation, if successful, will fill a gap of our knowledge in glyco-immunology related to allergic reactions and diseases.

Public Health Relevance

Antibodies are an important class of therapeutic glycoproteins. The Fc domain glycosylation is essential for antibody's biological functions. The proposed research aims to decipher the functional roles of Fc glycosylation through glycan engineering and Fc receptor binding studies, which could lay the foundation for discovery of novel antibody glycoforms with improved efficacy for anti-cancer and anti-inflammatory therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM096973-07
Application #
9459375
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Marino, Pamela
Project Start
2011-07-01
Project End
2020-12-31
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
7
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Maryland College Park
Department
Chemistry
Type
Earth Sciences/Resources
DUNS #
790934285
City
College Park
State
MD
Country
United States
Zip Code
20742
Li, Tiezheng; Li, Chao; Quan, David N et al. (2018) Site-specific immobilization of endoglycosidases for streamlined chemoenzymatic glycan remodeling of antibodies. Carbohydr Res 458-459:77-84
Giddens, John P; Lomino, Joseph V; DiLillo, David J et al. (2018) Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proc Natl Acad Sci U S A 115:12023-12027
Li, Chao; Wang, Lai-Xi (2018) Chemoenzymatic Methods for the Synthesis of Glycoproteins. Chem Rev 118:8359-8413
Bennett, Lindsay D; Yang, Qiang; Berquist, Brian R et al. (2018) Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies. Int J Mol Sci 19:
Tong, Xin; Li, Tiezheng; Orwenyo, Jared et al. (2018) One-pot enzymatic glycan remodeling of a therapeutic monoclonal antibody by endoglycosidase S (Endo-S) from Streptococcus pyogenes. Bioorg Med Chem 26:1347-1355
Li, Chao; Li, Tiezheng; Wang, Lai-Xi (2018) Chemoenzymatic Defucosylation of Therapeutic Antibodies for Enhanced Effector Functions Using Bacterial ?-Fucosidases. Methods Mol Biol 1827:367-380
Tong, Xin; Li, Tiezheng; Li, Chao et al. (2018) Generation and Comparative Kinetic Analysis of New Glycosynthase Mutants from Streptococcus pyogenes Endoglycosidases for Antibody Glycoengineering. Biochemistry 57:5239-5246
Li, Chao; Zhu, Shilei; Ma, Christopher et al. (2017) Designer ?1,6-Fucosidase Mutants Enable Direct Core Fucosylation of Intact N-Glycopeptides and N-Glycoproteins. J Am Chem Soc 139:15074-15087
Tang, Feng; Wang, Lai-Xi; Huang, Wei (2017) Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates. Nat Protoc 12:1702-1721
Li, Tiezheng; DiLillo, David J; Bournazos, Stylianos et al. (2017) Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A 114:3485-3490

Showing the most recent 10 out of 23 publications